A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome

Learn more about:
Related Clinical Trial
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome Natural History Study of Infants and Children With SCN1A-positive Dravet Syndrome An Open-Label Study to Investigate the Safety of Single Ascending Doses in Children and Adolescents With Dravet Syndrome Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol) The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects. GWPCARE5 – An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes Genetic Analysis Between Charlotte’s Web Responders Versus Non- Responders in a Dravet Population ZX008 Expanded Access Protocol The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) Verapamil as Therapy for Children and Young Adults With Dravet Syndrome A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥2 Years Old and Young Adults With Dravet Syndrome Stiripentol in Dravet Syndrome Compassionate Use of Stiripentol in Dravet Syndrome Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome

Brief Title

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome

Official Title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome

Brief Summary

      This is a multicenter, double-blind, parallel-group, placebo-controlled, study to assess the
      efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric
      and young adult subjects with Dravet syndrome. Subjects who qualify for the study will be
      randomized (1:1:1) in a double-blind manner to receive 1 of 2 doses of ZX008 or placebo. All
      subjects will be titrated to their randomized dose over a 14-day Titration Period. Following
      titration, subjects will continue treatment at their randomly assigned dose over a 12-week
      Maintenance Period. Total treatment time from the beginning of the Titration Period through
      the end of the Maintenance Period is 14 weeks.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Change from baseline in frequency of convulsive seizures in subjects receiving ZX008 0.8mg/kg/day compared to placebo

Secondary Outcome

 Change from baseline in frequency of convulsive seizures for subjects receiving ZX008 0.2mg/kg/day compared to placebo

Condition

Dravet Syndrome

Intervention

ZX008 - 0.8 mg/kg/day

Study Arms / Comparison Groups

 Experimental: ZX008 - 0.8 mg/kg/day
Description:  ZX008 is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

130

Start Date

July 15, 2016

Completion Date

July 2020

Primary Completion Date

July 2020

Eligibility Criteria

        Key Inclusion Criteria

          -  Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day
             of the Screening Visit.

          -  Clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely
             controlled by current antiepileptic drugs.

          -  Must have a minimum # of convulsive seizures per 4-week period for past 12 weeks prior
             to screening.

          -  All medications or interventions for epilepsy (including KD and VNS) must be stable
             for at least 4 weeks prior to screening and are expected to remain stable throughout
             the study.

          -  Parent/caregiver is willing and able to be compliant with diary completion, visit
             schedule and study drug accountability.

        Key Exclusion Criteria

          -  Pulmonary arterial hypertension.

          -  Current or past history of cardiovascular or cerebrovascular disease, such as cardiac
             valvulopathy, myocardial infarction or stroke.

          -  Current or past history of glaucoma.

          -  Moderate or severe hepatic impairment

          -  Receiving concomitant therapy with: centrally-acting anorectic agents;
             monoamine-oxidase inhibitors; medications that act via serotonin including serotonin
             reuptake inhibitors; atomoxetine, or other centrally-acting noradrenergic agonist;
             cyproheptadine, and/or CYP 2D6/3A4/2B6 inhibitors/substrates.

          -  Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or
             phenytoin, or has taken any of these within the past 30 days.

          -  Subject is unwilling to refrain from large or daily servings of grapefruits and/or
             Seville oranges, and their juices beginning with the Baseline Period and throughout
             the study.

          -  A clinically significant condition, or has had clinically relevant symptoms or a
             clinically significant illness in the 4 weeks prior to the Screening Visit, other than
             epilepsy, that would negatively impact study participation, collection of study data,
             or pose a risk to the subject.

          -  Currently receiving an investigational product.
      

Gender

All

Ages

2 Years - 18 Years

Accepts Healthy Volunteers

No

Contacts

, 510-388-9968, [email protected]

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT02826863

Organization ID

ZX008-1502


Responsible Party

Sponsor

Study Sponsor

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.


Study Sponsor

, , 


Verification Date

January 2020